Source Natural Foods & Herbal Supplements Ltd (531398)

Healthcare · Pharmaceuticals · NSE · Updated 13 September 2026
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
₹107 ↓ 20.71% (1Y)

🎯 Key Takeaways

  • Source Natural Foods & Herbal Supplements Ltd is transitioning from a traditional herbal supplements business toward a dual-track strategy with renewable energy expansion, marked by the incorporation of its solar-focused subsidiary SN Solar Mangaluru Private Limited in August 2026. The company maintains a conservative balance sheet with minimal debt and stable promoter holding, but financial performance remains flat, with stagnant revenue and margins over the past year.
  • Revenue grew 1.5% QoQ to ₹21 in Q1FY27.
  • ⚠️ 1) Core herbal supplements business shows no growth momentum, with flat revenue and margins over multiple periods. 2) Entry into solar energy carries
Market Cap
₹69
P/B Ratio
3.08
Debt/Equity
0.33
Promoter
74.4%

📖 The Story

Source Natural Foods & Herbal Supplements Ltd is transitioning from a traditional herbal supplements business toward a dual-track strategy with renewable energy expansion, marked by the incorporation of its solar-focused subsidiary SN Solar Mangaluru Private Limited in August 2026. The company maintains a conservative balance sheet with minimal debt and stable promoter holding, but financial performance remains flat, with stagnant revenue and margins over the past year.

📰 What's Happening

The company incorporated SN Solar Mangaluru Private Limited on August 31, 2026, to develop solar PV projects, signaling a strategic pivot into renewable energy infrastructure. This move is part of broader regulatory and operational restructuring, creating a dedicated vehicle for clean energy investments while preserving full ownership control. No operational updates or project timelines were disclosed in the filing.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

MetricJun 2025Mar 2026Jun 2026
Revenue122121
Operating Profit121
OPM %8.3%10.2%4.8%
Net Profit111
EPS₹0.98₹1.93₹1.06

Revenue has plateaued over the past two years, declining from ₹12 crore in June 2025 to ₹21 crore in June 2026, with operating margins fluctuating between 4.8% and 10.2% and net profit remaining flat at ₹1 crore. Despite higher revenue in recent quarters, profitability has not improved meaningfully, suggesting pricing pressure or cost inefficiencies in core operations.

🔮 Management Outlook & What's Next

Management has not provided forward guidance on revenue, margins, or growth expectations for either the herbal supplements or solar segments in the latest filings. The incorporation of SN Solar Mangaluru is framed as a compliance-driven step rather than a growth announcement, leaving future capital allocation and operational plans unspecified.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

ItemMar 2025Mar 2025Mar 2026Mar 2026
Equity Capital6666
Reserves14161719
Borrowings6778
Total Liabilities31364141
Fixed Assets4544
Investments0000
Total Assets31364141

The balance sheet remains stable with minimal leverage (D/E of 0.33), consistent equity of ₹6 crore, and rising reserves. Total assets have increased modestly from ₹36 crore to ₹41 crore, reflecting incremental investments likely tied to subsidiary setup, though no major capex or financing activity is evident in cash flow data.

💰 Cash Flow Statement (₹ Cr)

ItemMar 2025
Operating+0
Investing-5
Financing+5
Net Cash Flow+0

👥 Shareholding Pattern

CategoryQ2FY26Q3FY26Q4FY26Q1FY27
Promoters74.4%74.4%74.4%74.4%
FII0.0%0.0%0.0%0.0%
DII0.0%0.0%0.0%0.0%
Public18.8%18.7%18.7%19.6%
# Shareholders3,7783,7053,6383,628

Promoter holding remains stable at 74.37% with no signs of dilution or sale, while public shareholding has slightly declined due to growing shareholder count. FII and DII holdings are consistently zero, indicating limited institutional interest or accessibility, and no recent changes in shareholder composition.

⚖️ Peer Comparison — Pharmaceuticals

Company MCap (₹ Cr) P/E ROCE ROE D/E
SUNPHARMA 4.42 L Cr 36.5 18.7% 14.6% 0.05
DIVISLAB 2.48 L Cr 84.6 23.0% 17.4% 0.00
TORNTPHARM 1.89 L Cr 79.4 15.1% 25.7% 1.76
ZYDUSLIFE 1.12 L Cr 24.9 16.8% 16.6% 0.43
CIPLA 1.10 L Cr 32.7 13.2% 9.8% 0.01
LAURUSLABS 1.06 L Cr 97.3 20.8% 20.6% 0.45
DRREDDY 96,906 30.0 10.1% 8.4% 0.17
AUROPHARMA 96,402 26.2 12.8% 9.8% 0.20
LUPIN 95,836 16.9 27.9% 24.7% 0.26
MANKIND 94,039 46.0 13.9% 12.7% 0.38

⚠️ Risk Factors

1) Core herbal supplements business shows no growth momentum, with flat revenue and margins over multiple periods. 2) Entry into solar energy carries execution and regulatory risks without disclosed project pipeline or revenue contribution timelines. 3) Lack of institutional ownership may limit liquidity and analyst coverage. 4) No forward guidance or strategic roadmap has been provided for either business segment.

🧠 Analyst's Read

The company is in an early-stage transformation with limited visibility into how its solar ambitions will contribute to future value creation. Investors should monitor upcoming disclosures for project updates, capital allocation plans, or operational metrics from SN Solar Mangaluru to assess the viability of this strategic shift.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-13.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts for your stocks — summarized by AI daily

Set up your AI Radar — pick stocks, get daily email summaries of new filings.

Set up AI Radar — Free

Free account · 2 AI queries/day